UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000059759 |
|---|---|
| Receipt number | R000060372 |
| Scientific Title | Descriptive statistics of WHO-HPQ and SPQ in the Japanese workplace |
| Date of disclosure of the study information | 2025/11/14 |
| Last modified on | 2025/11/13 13:19:47 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Descriptive statistics of WHO-HPQ and SPQ in the Japanese workplace
Acronym
Descriptive statistics of WHO-HPQ and SPQ in the Japanese workplace
Scientific Title
Descriptive statistics of WHO-HPQ and SPQ in the Japanese workplace
Scientific Title:Acronym
Descriptive statistics of WHO-HPQ and SPQ in the Japanese workplace
Region
| Japan |
Condition
Condition
none
Classification by specialty
| Adult |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
Descriptive statistics of WHO-HPQ and SPQ in the Japanese workplace
Basic objectives2
Others
Basic objectives -Others
none
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
the World Health Organization Health and Work Performance Questionnaire (WHO-HPQ)
Key secondary outcomes
Single-Item Presenteeism Question (SPQ)
Base
Study type
Observational
Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| Not applicable |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
none
Key exclusion criteria
none
Target sample size
900000
Research contact person
Name of lead principal investigator
| 1st name | Anna |
| Middle name | |
| Last name | Tozawa |
Organization
ADVANTAGE Risk Management Co., Ltd.
Division name
Research Department
Zip code
153-0051
Address
17F Nakameguro GT tower 2-1-1 Kamimeguro Meguro-ku, Tokyo, Japan
TEL
03-5794-3817
atozawa@armg.jp
Public contact
Name of contact person
| 1st name | Anna |
| Middle name | |
| Last name | Tozawa |
Organization
ADVANTAGE Risk Management Co., Ltd.
Division name
Research Department
Zip code
153-0051
Address
17F Nakameguro GT tower 2-1-1 Kamimeguro Meguro-ku, Tokyo, Japan
TEL
03-5794-3817
Homepage URL
atozawa@armg.jp
Sponsor or person
Institute
ADVANTAGE Risk Management Co., Ltd.
Institute
Department
Personal name
Funding Source
Organization
ADVANTAGE Risk Management Co., Ltd.
Organization
Division
Category of Funding Organization
Profit organization
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
ADVANTAGE Risk Management Co., Ltd.
Address
17F Nakameguro GT tower 2-1-1 Kamimeguro Meguro-ku, Tokyo, Japan
Tel
03-5794-3817
snakagawa@armg.jp
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2025 | Year | 11 | Month | 14 | Day |
Related information
URL releasing protocol
This item cannot be registered because it is prior to analysis.
Publication of results
Unpublished
Result
URL related to results and publications
This item cannot be registered because it is prior to analysis.
Number of participants that the trial has enrolled
900000
Results
It has been 12 months since the scheduled end date of the follow-up, but it cannot be published as it is still pending analysis.
Results date posted
| 2025 | Year | 11 | Month | 13 | Day |
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
It has been 12 months since the scheduled end date of the follow-up, but it cannot be published as it is still pending analysis.
Participant flow
It has been 12 months since the scheduled end date of the follow-up, but it cannot be published as it is still pending analysis.
Adverse events
It has been 12 months since the scheduled end date of the follow-up, but it cannot be published as it is still pending analysis.
Outcome measures
It has been 12 months since the scheduled end date of the follow-up, but it cannot be published as it is still pending analysis.
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Preinitiation
Date of protocol fixation
| 2024 | Year | 03 | Month | 27 | Day |
Date of IRB
| 2024 | Year | 04 | Month | 09 | Day |
Anticipated trial start date
| 2024 | Year | 04 | Month | 09 | Day |
Last follow-up date
| 2024 | Year | 04 | Month | 09 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
none
Management information
Registered date
| 2025 | Year | 11 | Month | 13 | Day |
Last modified on
| 2025 | Year | 11 | Month | 13 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000060372
